Skip to main content

Analysts Have Conflicting Sentiments on These Healthcare Companies: Align Tech (ALGN) and ProQR (PRQR)

Tipranks - Tipranks - Wed Oct 22, 2025

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Align Tech (ALGN – Research Report) and ProQR (PRQR – Research Report).

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Align Tech (ALGN)

In a report released today, Erin Wright from Morgan Stanley maintained a Hold rating on Align Tech, with a price target of $142.00. The company’s shares closed last Monday at $134.93.

According to TipRanks.com, Wright is a 5-star analyst with an average return of 14.3% and a 66.1% success rate. Wright covers the Healthcare sector, focusing on stocks such as BrightSpring Health Services, Inc., Elanco Animal Health, and Phibro Animal Health. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Align Tech with a $169.75 average price target, implying a 28.0% upside from current levels. In a report issued on October 10, Jefferies also downgraded the stock to Hold with a $140.00 price target.

See today’s best-performing stocks on TipRanks >>

ProQR (PRQR)

In a report released today, Ananda Ghosh from H.C. Wainwright maintained a Buy rating on ProQR, with a price target of $12.00. The company’s shares closed last Monday at $3.05.

According to TipRanks.com, Ghosh is a 5-star analyst with an average return of 43.7% and a 75.7% success rate. Ghosh covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Maze Therapeutics, Inc., and ACADIA Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for ProQR with a $8.33 average price target, representing a 193.3% upside. In a report issued on October 15, Citizens JMP also reiterated a Buy rating on the stock with a $8.00 price target.

Read More on ALGN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).